News | August 12, 2021
Natco Pharma PAT at Rs 75 crore for Q1FY22
The company has strong product launches both in India and overseas
The company has strong product launches both in India and overseas
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
If approved it will bring a second source of MMR vaccine to the US market
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
A veteran in cell therapy and oncology commercialisation
Subscribe To Our Newsletter & Stay Updated
